ONCOL: Prof. Hirsh， welcome to CSCO meeting， what are your feelings about CSCO 2017? 

 

　　Prof. Hirsh：This year， I had the pleasure of being here before， is very encouraging， very inspiring， and I see rapid progress in development of oncology in Asia in general， and particularly of course in China. We are impressed of seeing Asian investigators and Asian led clinical trials. Many of them are landmark trials and they have changed the whole feel and it is very impressive to see how the Chinese oncology community comes together and do those studies with other Asian investigators as well. So from our point of view this is very encouraging and inspiring. 

 

　　ONCOL: Prof. Hirsh and Prof. Wu，this?year?marks?the 20th?anniversary of CSCO， how?do?you?see the role of CSCO has played in oncology community in the past two decades? 

　　Prof. Wu: Recently， five-year ago the goal of the CSCO was to developed international understanding in the academic part. I think that we have a very good cooperation with the IALSC， such as at the CSCO annual meeting we have the CSCO and IALSC annual meeting. And also in the world lung cancer meeting with the IALSC we also have a very special session. We have the three-year joint session XXX and then I think this is a good cooperation to promote lung cancer treatment in a global perspective and then to promote the China lung cancer treatment forward. I think this is why cooperation is very， very important. 

 

　　Prof. Hirsh: From a sincere point of view， the collaboration with CSCO and the Asian investigators is very， very important. I would like to see in the future much more formal collaboration with CSCO. We have had the joint session for several years， but might be in the future we will do more other collaborative activities， both educational and scientifically. And that should be our strategy in the future. 

 

　　Prof. Wu: I totally agree because now we have the developed the subject area and program， open to Chinese young physicians. Also I think that we have developed much more the workshop in China. This is the front of our cooperation.

 

　　ONCOL: A?collaborative?joint?symposium?between?CSCO and IASLC?was hold today， there are topics about EGFR， ALK，CNS metastasis， biomarker and immunotherapy. Would you please share your considerations for choosing the topics of CSCO-IASLC Joint Symposium? 

 

　　Prof. Wu: We have developed this program for a long time， after the last year’s CSCO meeting and then we had discussions so many times with the IASLC which topic we need in this year. So， yes it is true， some of the topic are very hot， especially in China， because China have so many patients with driver gene XX EGFR， about 40% of EGFR. And also now we have so many drugs that could be used in the clinical practice， so I think the topic how to choose the ALK-TKI and how to sequence that using the ALK-TKI. So this is a hot topic because we have so many many clinical practice problems needed to be checked. And the second point I think immunotherapy is so very very pricing， and also need more and more technology， and more and more clinical trials on the immunotherapy which is why we choose immunotherapy in the regime as our hot topic. 

 

　　Prof. Hirsh: Yeah， I agree entirely with what Professor Wu is saying. I could add that there might be other topics in the future we could put into the joint sessions. One focus could be early stage disease， there is a lot of interest in early stage disease these days， both related to adjuvant therapy， as a matter of fact also neo-adjuvant therapy. And for stage 3 disease now also combined modalities including immunotherapy. So I could foresee several other topics also relevant for a joint session in the future.